WHAT ELSE YOU CAN DO TO HELP

Dear Friends of Sarcoma Research,

The current legislative and regulatory landscape may present many opportunities -- as well as many challenges -- to the Sarcoma community.

The Sarcoma Foundation of America (SFA) is actively seeking to ensure that the Food and Drug Administration (FDA) recognize alternatives or surrogates to traditional clinical trial endpoints.  The SFA firmly believes that FDA acceptance of clinical endpoints other than overall survival could remove many of the present barriers in the development of drugs to treat rare cancers such as Sarcomas.  The SFA is working to find a solution to this issue, with the goal of having language directing the FDA to recognize alternate endpoints included in the appropriate legislative vehicle.  In addition, the SFA has also been urging the FDA to include language in a Congressionally-mandated report and guidance that acknowledges acceptance of clinical endpoints other than overall survival. 
 

For more information on the efforts taking place, please visit www.curesarcoma.org/index.php/advocacy/.

The most serious challenge to date concerns federal funding of cancer research.   Congress is in the process of funding the government for the remainder of the 2011 fiscal year.  Unfortunately, a proposal in the U.S. House of Representatives contains significant and drastic cuts in funding to the National Institutes of Health (NIH). Slashing the NIH budget puts federal cancer research in serious jeopardy.  Rare cancers such as Sarcoma, which make up a little more than 1 percent of all adult cancers, already face challenges receiving its fair share of research dollars.  Serious cuts to the NIH budget will only make it that more difficult for Sarcoma research to get the attention it deserves.
 

The Sarcoma Foundation of America asks for your support -- and your voice -- for those who are already suffering from a cancer with no cure and few treatment options.  We strongly urge you to contact your Representative and insist that they oppose the drastic funding cuts to the NIH budget.
 

To contact your Representative, please click here:
Contact your Representative.
 

Thank you for your continued support.
 

Sincerely,
Matthew Alsante
Executive Director
Sarcoma Foundation of America